Who Owns Ozempic?

Sustainable Manufacturing: Novo Nordisk has committed to powering all production with renewable energy and has implemented carbon reduction initiatives across its manufacturing network. The company's 2025 annual report highlighted environmental targets including reduced CO2 emissions from operations and transportation.

Patient Access Programs: Novo Nordisk operates NovoCare, a patient support platform that provides assistance programs for uninsured or underinsured patients. The MFN agreement with the U.S. Administration, reached in November 2025, is intended to broaden access to semaglutide medicines through Medicare Part D, Medicaid, and direct-to-patient self-pay options. The Bridge pilot program, implemented from July 1, 2026, provides Medicare Part D coverage for obesity medicines.

Clinical Research: Novo Nordisk conducts extensive clinical trials for semaglutide across multiple indications. The SUSTAIN trial program for Ozempic and the SELECT cardiovascular outcomes trial have been published in peer-reviewed medical journals. The company continues to research new indications and formulations, including the 25 mg oral tablet dose submitted for FDA approval in 2026.

Supply Chain Investment: Novo Nordisk is investing approximately DKK 55 billion in 2026 to expand global manufacturing capacity for semaglutide products. This investment addresses the supply shortages that affected diabetes patients in 2022 and 2023 and supports the growing global demand for GLP-1 medications.

Ozempic has been recognized by medical associations and pharmaceutical industry organizations as a significant advancement in type 2 diabetes treatment. The SUSTAIN-6 cardiovascular outcomes trial, published in the New England Journal of Medicine, has been cited in diabetes treatment guidelines worldwide.

The development of semaglutide has received innovation recognition from pharmaceutical industry organizations. Novo Nordisk's work on GLP-1 receptor agonists, from the initial Victoza (liraglutide) through to Ozempic (semaglutide) and the oral formulation, represents one of the most commercially successful pharmaceutical research programs of the 2020s.

Ozempic's patient assistance programs have received recognition from patient advocacy groups for improving access to diabetes medication, though the high list price of the drug has also drawn criticism from the same groups.

Side Effects and Boxed Warning: Ozempic carries an FDA boxed warning about the potential risk of thyroid C-cell tumors. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects include nausea, vomiting, diarrhea, and constipation. More serious but rare risks include pancreatitis, kidney injury, and gallbladder disease.

Supply Shortages (2022-2024): Off-label use of Ozempic for weight loss, driven by social media attention and celebrity endorsements, created significant supply shortages in 2022 and 2023. Diabetes patients who relied on Ozempic for blood sugar control reported difficulty filling prescriptions. The FDA and Novo Nordisk both issued statements urging against off-label use. Novo Nordisk invested heavily in manufacturing expansion to address the shortages, and supply has improved in 2025 and 2026.

Pricing and Access: The list price of Ozempic in the U.S. exceeds $900 per month without insurance, which has drawn criticism from patient advocates, politicians, and healthcare organizations. The MFN agreement reached in November 2025 with the U.S. Administration is intended to lower costs for patients covered by Medicare and Medicaid. Novo Nordisk has stated that the agreement will bring GLP-1 medications to more Americans at a lower cost, but the impact on the company's realized prices has been negative, contributing to the 2026 sales decline in U.S. operations.

Off-Label Use: The widespread off-label use of Ozempic for weight loss, rather than its FDA-approved indication of type 2 diabetes, generated significant controversy. Healthcare providers and regulators expressed concern about appropriate prescribing practices. Novo Nordisk has stated that it does not promote Ozempic for weight loss and directs patients seeking weight loss treatment to Wegovy, which is approved for chronic weight management.

Competition and Market Share Loss: Eli Lilly's tirzepatide products (Mounjaro and Zepbound) have gained market share over semaglutide in the GLP-1 market. Novo Nordisk's 2026 guidance explicitly acknowledges intensifying competition and a sales decline in U.S. operations. The company's stock price declined significantly from its 2024 peak as investors adjusted expectations for the competitive landscape.

Compound Patent Expiry: The compound patent for the semaglutide molecule has expired in certain international markets, allowing generic competitors to enter. Novo Nordisk noted this as a factor in its 2026 guidance, particularly for International Operations where generic semaglutide may reduce market share.